Photo via Daily Mail

'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain

Read the original at Daily Mail ↗
Cite

Hardy, Z. (2026, September 30). 'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain. Daily Mail. https://www.dailymail.com/health/article-16169509/Godzilla-fat-jab-retatrutide-UK.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Daily Mail · collected 2026-09-30 · by Zoe Hardy

Quick Summary

A new drug called Retatrutide, nicknamed the 'Godzilla' fat jab or 'Reta', is showing promising results in clinical trials for weight loss among obese patients with type 2 diabetes. In a phase 3 trial involving 1,152 participants from eight countries, those on the highest dose of Retatrutide lost up to a quarter of their body weight over 18 months, compared to around 20% for Mounjaro over a similar period. The drug targets three hormone pathways and is expected to be available on the NHS in Britain within about three years.
Written by AI on 2026-09-30, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Eli Lilly's experimental drug retatrutide showed promising results for weight loss among people with Type 2 diabetes, according to studies published in The Lancet and New England Journal of Medicine. In one trial, participants taking the highest dose lost an average of 18.8% of their starting body weight over 1.5 years, compared to just 5.1% for those on placebo. Some patients lost up to 60 pounds (23%) of their initial weight, marking it as the most potent drug tested in diabetes care so far. Additionally, retatrutide not only aids significant weight loss but also improves blood sugar control; about 63% of participants lowered their A1C levels below 6.5%, which is indicative of better diabetes management. The drug's unique mechanism—targeting three hormone pathways instead of one or two—may contribute to its effectiveness compared to other GLP-1 drugs like Ozempic and Wegovy (semaglutide), as well as Mounjaro (tirzepatide).

Written for “Lilly Weight Loss Drug Trials” on 2026-11-18, grounded in this article and the 2 other(s) covering the same event.

How they differ

3 outlets covered “Lilly Weight Loss Drug Trials”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Daily MailThis outlet30 Sep

A new drug called Retatrutide, nicknamed the 'Godzilla' fat jab or 'Reta', is showing promising results in clinical trials for weight loss among obese patients with type 2 diabetes. In a phase 3 trial involving 1,152 participants from eight countries, those on the highest dose of Retatrutide lost up to a quarter of their body weight over 18 months, compared to around 20% for Mounjaro over a similar period. The drug…

'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain (this article)
Time29 Sep

Eli Lilly’s experimental weight-loss drug, retatrutide, showed significant effectiveness in two studies published in The Lancet and the New England Journal of Medicine. Participants with Type 2 diabetes who took the highest dose lost an average of 18.8% of their body weight over a year and a half, compared to 5.1% for those on placebo. In a separate study focusing on overweight or obese individuals without diabetes…

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results →
NBC News29 Sep

Eli Lilly's GLP-1 drug retatrutide helped people with Type 2 diabetes lose up to 60 pounds, or about 23% of their body weight, according to a late-stage trial published in The Lancet. This result is the highest recorded weight loss for a diabetes medication and compares favorably to semaglutide and tirzepatide, which resulted in up to 10% and 15% weight loss respectively. Dr. Susan Spratt of Duke Health highlighted…

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug →

Where they agree and split

Framing

How the first headlines put it

Stated as fact3
The headlines (3)

Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results Time · stated as fact

People with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug NBC News · stated as fact

'Godzilla' fat jab retatrutide sheds more fat than Mounjaro, new study finds - here's when you can get it in Britain Daily Mail · stated as fact

The full story: what happened, how it changed, and all 3 articles →

Compared with similar articles

This article reads unscored and hedges 24% of its claims. Each row says how that neighbour differs.
NBC News
Hedges 7 of 34 claims Outlet record 78/100
TIME
Hedges 1 of 15 claims Outlet record 60/100
New York Post
Hedges 0 of 23 claims Outlet record 66/100
“While both articles discuss retatrutide (also known as 'Godzilla' or 'triple-G'), they describe different aspects of its development and research findings.”

Story

Lilly Weight Loss Drug Trials
Health · 3 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
33
sentences that state something as happening or true
Uncertain
24%
8 of 33 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
70/100
Daily Mail's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
3
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-09-30 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Daily Mail · 11752 article(s) · 24 correction(s) detected
Running correction rate · 24 correction(s)

Who wrote this

Zoe Hardy
14 article(s) here · 1 carrying a prediction
For most otherwise fit and healthy people – and for most doctors – these symptoms would not ring alarm bells.
What's more, an alarming study published earlier this year suggested that ditching carbohydrates could encourage the growth of cancerous tumours.
In the UK, advertising prescription-only medications – which includes all weight loss jabs such as Wegovy and Mounjaro – to the public is illegal It says the move will help set clear precedents for advertisers.
A new-generation weight loss jab that destroys fat under the skin could give overweight adults a flat stomach in just a few months, a study suggests.
Researchers suggested this may be linked to the increased speed of weight-loss triggered by the drugs, which can put the body under stress.
The 'Godzilla' fat jab could rival Mounjaro by helping users shed up to a quarter of their body weight while improving blood pressure and cholesterol, research has found.
The global market for menopause supplements is expected to surpass £18.4million by 2030.
One in eight cancers worldwide could be triggered by infections, many of which can be prevented through vaccinations, a study has found.
The researchers concluded: 'Our findings suggest reducing consumption of UPFs and replacing them with minimally processed alternatives could help prevent chronic disease and reduce the burden on health services.'
'However, as outcomes for these complications improve, cancer may require greater attention.'
Also by Zoe Hardy
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 14 articles by Zoe Hardy →

Topics

Los Angeles Institute for Metabolic Research Mounjaro NHS Reta Retatrutide

Subjects

NHS ORG · 2× Eli Lilly ORG · 1× Los Angeles Institute for Metabolic Research ORG · 1× Milan GPE · 1×

Narrative

Eli Lilly were forced to issue warnings when promising results from early stage trials led to a surge in people trying to obtain the drug through social media The company said those using fake drugs from unauthorised sources are putting their health at 'serious risk' and threatened to take action against the sellers.
framing: mixed · carried by 1 article(s) · first seen 2026-09-30
The 'Godzilla' fat jab could rival Mounjaro by helping users shed up to a quarter of their body weight while improving blood pressure and cholesterol, research has found.

Claims (33 extracted, 8 hedged)

The 'Godzilla' fat jab could rival Mounjaro by helping users shed up to a quarter of their body weight while improving blood pressure and cholesterol, research has found. uncertain
research → rival → pressure
According to US researchers, Retatrutide is the best drug yet for obese or overweight patients with type 2 diabetes, who typically lose less weight on the blockbuster jabs than people without the condition. uncertain
who → accord → condition
The drug, commonly known as 'Reta', is still undergoing clinical trials but has been hailed as a potential 'game changer' for weight-loss, heart disease and osteoarthritis. asserted
drug → know → loss
Now experts at Los Angeles Institute for Metabolic Research have found that nearly a third of users taking the highest dose can shed at least a quarter of their body weight over a period of 18 months. asserted
third → find → months
The most powerful licensed weight loss drug currently available, Mounjaro, helps users lose around 20.9 per cent of their body weight when taken for 16-and-a-half months. asserted
users → license → months
Retatrutide – also known as 'triple G' – is a triple agonist, meaning it targets three hormone pathways involved in appetite control to help the body burn fat, including GLP-1. asserted
body → know → GLP-1
The latest findings come from TRIUMPH-2, a phase 3 clinical trial evaluating the effectiveness and safety of retatrutide in 1,152 overweight and obese adults with type 2 diabetes. asserted
findings → come → diabetes
The triple whammy drug could be available on the NHS in three years Participants from eight countries were randomly assigned to receive weekly injections of retatrutide at doses of 4mg, 9mg or 12mg – or a placebo, alongside diet and exercise advice. uncertain
Participants → assign → advice
On average, participants had been obese for more than two decades and were diagnosed with type 2 diabetes at least five years before the study started. asserted
study → diagnose → diabetes
After 80 weeks, participants taking the strongest 12mg dose lost nearly a fifth of their body weight compared with 17 per cent on the 9mg dose and 12 per cent on the 4mg dose. asserted
participants → take → dose
Almost half of those on the highest dose lost at least a fifth of their body weight, while nearly one in three shed at least a quarter. asserted
three → lose → quarter
Those given a placebo lost just five per cent of their weight through diet and exercise alone. asserted
Those → give → diet
For a typical 5ft 10in obese man, the average weight loss seen on the highest dose would equate to roughly 23kg, or more than three-and-a-half stone, over 18 months. asserted
loss → see → months
Retatrutide was also found to dramatically improve blood sugar levels, helping patients control diabetes and, in some cases, put the condition into remission. asserted
patients → find → remission
Nearly three quarters of patients on the highest dose achieved blood sugar levels at or below the target used to diagnose diabetes, compared with just 29 per cent of those given a placebo. asserted
quarters → achieve → placebo
Participants also showed significant improvements across other cardiovascular risk factors, including bad cholesterol and inflammation. asserted
Participants → show → cholesterol
However, like all other GLP-1 jabs, retatrutide was found to cause a number of side-effects, including nausea and diarrhoea. asserted
retatrutide → find → nausea
Abnormal skin sensations including burning and discomfort also occurred in seven per cent of participants on the highest dose. asserted
sensations → include → dose
Seven deaths also occurred over the course of the study, which were deemed unrelated to the treatment by investigators. asserted
which → occur → investigators
Presenting their findings at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, the authors concluded: 'Retatrutide may advance the treatment of obesity and type 2 diabetes, a population where weight reduction has been challenging to achieve.' uncertain
reduction → present → obesity
They added that the safety profile of the drug is generally similar to the other weight loss jabs. asserted
profile → add → jabs
Further research is expected to determine whether these benefits translate to improvements in other obesity-related complications such as sleep apnoea, strokes, heart disease and cancer. asserted
benefits → expect → apnoea
The latest findings follow a surge in interest in the drug after early-stage trials suggested it may result in more significant weight loss than Ozempic and Mounjaro. uncertain
it → follow → Ozempic
Eli Lilly, the pharmaceutical firm behind retatrutide, was forced to issue warnings against trying to obtain the drug via social media. asserted
Lilly → force → media
Eli Lilly were forced to issue warnings when promising results from early stage trials led to a surge in people trying to obtain the drug through social media The company said those using fake drugs from unauthorised sources are putting their health at 'serious risk' and threatened to take action against the sellers. asserted
those → force → sellers
Earlier this year the Daily Mail revealed a man in his thirties died after taking an unapproved version of the drug – with dozens more having suffered serious side effects. asserted
dozens → reveal → effects
Since 2025, the Medicines and Healthcare products Regulatory Agency (MHRA), has recorded 77 reports of suspected retatrutide side effects – but added that reports alone do not prove that a medicine caused the suspected adverse reaction. asserted
medicine → record → reaction
Retatrutide is not currently approved or available on the NHS, but could be available to buy and even be prescribed on the NHS within three years if approved by regulators, experts say. uncertain
experts → approve → regulators
Separate research presented at EASD found an experimental drug called petrelintide could offer similar weight-loss to Mounjaro, but with fewer side effects than existing blockbuster jabs. uncertain
drug → present → jabs
Rather than targeting GLP-1 hormones that regulate appetite and slow digestion, petrelintide mimics the hormone amyline, helping people feel fuller for longer. asserted
people → target → longer
Participants lost around 10 per cent of their body weight in under 10 months, while also seeing improvements in blood pressure and cholesterol levels. asserted
Participants → lose → pressure
Experts say its main attraction is its tolerability – with users suffering far less unpleasant digestive side effects than typically seen with GLP-1s. asserted
users → say → GLP-1s
Scientists not involved in the study said further research is needed, including a direct head-to-head comparison with Mounjaro and Wegovy, to support these claims. uncertain
research → involve → claims
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support